Immutep receives about A$1.13M R&D tax incentive from Australian govt

Stock Information for Immutep Limited

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Immutep Limited

Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
Immutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Translational Data and Significant Pathologic Response Rates from EFTISARC-NEO Phase II Highlighted in Oral Presentation at CTOS 2025
Immutep Receives A$4.6 million R&D Tax Incentive from French Government
Immutep Quarterly Activities Report Q1 FY26
Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025
Two Posters at ESMO Congress 2025 Highlight Immutep's Focus on Changing Treatment Landscape in First Line Non-Small Cell Lung Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.